Study of Hepatitis B Virus in the Liver
Part of Digestive system, Infections clinical trials.
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic hepatitis B infection (any stage).
- You may or may not be taking antiviral medication.
- You may or may not have hepatitis D co-infection.
- You are already part of another study (CirB-RNA) and have signed a consent form.
- You do not have advanced liver scarring, liver cancer, or a liver transplant.
- You are not pregnant or breastfeeding.
- You do not have active hepatitis C or HIV infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a newer, more precise way of measuring the amount of hepatitis B virus in your blood (called digital PCR) to see if it matches current testing methods. If you are a chronic hepatitis B patient, this could help make future virus monitoring more accurate.
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
This study looks at how a specific protein (ANKRD11) affects immune cells in people with chronic hepatitis B. By understanding this, researchers hope to find ways to help your immune system fight the virus better.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.